| Literature DB >> 9934776 |
M Raderer1, M H Hejna, A Kurtaran, G V Kornek, J B Valencak, G Oberhuber, F Vorbeck, I Virgolini, W Scheithauer.
Abstract
Treatment options for hepatocellular cancer apart from surgical resection are limited because of the drug-refractory nature of this disease. Little is known about the role of somatostatin-receptors in hepatocellular cancer, and somatostatin analogs have not been investigated for treatment of this malignancy. We present the case of a 68-yr-old male, who was successfully treated with the long-acting somatostatin analog lanreotide.Entities:
Mesh：
Substances：
Year: 1999 PMID： 9934776 DOI： 10.1111/j.1572-0241.1999.00821.x
Source DB: PubMed Journal: Am J Gastroenterol ISSN： 0002-9270 Impact factor: 10.864